Formation of a Gemcitabine (dFdC) Acquired Resistant BT 549 Triple Negative Breast Cancer Cells

Triple negative breast cancer (TNBC) is an aggressive variant of breast cancer (BC). TNBC can develop an acquired resistance after repeated exposure to anticancer drugs, which remains a major hurdle for the success of chemotherapy. The relapsed TNBC is commonly pan-resistant to various drugs with completely different resistant mechanisms. Gemcitabine BT549 cells were developed from white-type cells. The acquired resistant cells were observed to show high resistance to Gemcitabine, in addition they were also found to be cross resistant to 3 anticancer drugs (Vincristine, Doxorubicin and Paclitaxel). These acquired resistant cell can be used as models to further study the various mechanisms of resistance in cancer cells.